How big is Alnylam Pharmaceuticals, Inc.?

As of Jun 18, Alnylam Pharmaceuticals, Inc. has a market capitalization of $40.25 billion, with recent net sales of $2.35 billion and a net profit of -$269.70 million.

Market Cap: As of Jun 18, Alnylam Pharmaceuticals, Inc. has a market capitalization of 40,252.20 million, categorizing it as a Mid Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Alnylam Pharmaceuticals, Inc. reported net sales of 2,348.11 million and a net profit of -269.70 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 67.09 million and total assets of 4,301.82 million.

What does Alnylam Pharmaceuticals, Inc. do?

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing RNA interference therapeutics, with recent net sales of $594 million and a market cap of approximately $40.25 billion. The company is currently operating at a loss, with a net profit of -$57 million.

Overview: <BR>Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery, development, and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics, operating within the Pharmaceuticals & Biotechnology industry and classified as a mid-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 594 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -57 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 40,252.20 Million (Mid Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.21 <BR>Return on Equity: -42.12% <BR>Price to Book: 348.70<BR><BR>Contact Details: <BR>Address: 675 W Kendall St, CAMBRIDGE MA: 02142-1168 <BR>Tel: 1 617 5518200 <BR>Fax: 1 617 5518101 <BR>Website: https://www.alnylam.com/

Who are in the management team of Alnylam Pharmaceuticals, Inc.?

As of March 2022, the management team of Alnylam Pharmaceuticals, Inc. includes CEO Dr. John Maraganore and Independent Chairman Mr. Michael Bonney, along with several independent directors such as Dr. Margaret Hamburg and Dr. Steven Paul. This team provides governance and strategic direction for the company.

As of March 2022, the management team of Alnylam Pharmaceuticals, Inc. includes the following individuals:<BR><BR>- Mr. Michael Bonney, Independent Chairman of the Board<BR>- Dr. John Maraganore, Chief Executive Officer and Director<BR>- Mr. Olivier Brandicourt, Director<BR>- Dr. Dennis Ausiello, Independent Director<BR>- Ms. Marsha Fanucci, Independent Director<BR>- Dr. Margaret Hamburg, Independent Director<BR>- Dr. Steven Paul, Independent Director<BR><BR>This team comprises a mix of executive leadership and independent directors, contributing to the governance and strategic direction of the company.

Should I buy, sell or hold Alnylam Pharmaceuticals, Inc.?

Is Alnylam Pharmaceuticals, Inc. technically bullish or bearish?

As of October 31, 2025, Alnylam Pharmaceuticals has a mildly bullish technical trend, supported by monthly indicators and daily moving averages, despite some bearish signals in the weekly timeframe, and it has significantly outperformed the S&P 500 year-to-date and over the past three years.

As of 31 October 2025, the technical trend for Alnylam Pharmaceuticals, Inc. has changed from bullish to mildly bullish. The weekly MACD and KST indicators are mildly bearish, while the monthly MACD and KST are bullish. The Bollinger Bands show a mildly bullish stance on both weekly and monthly time frames, and daily moving averages are also mildly bullish. However, Dow Theory indicates a mildly bearish trend on both weekly and monthly bases. <BR><BR>In terms of performance, Alnylam has significantly outperformed the S&P 500 year-to-date with a return of 79.96% compared to 16.30%, and over the past three years, it has returned 96.31% versus the S&P 500's 76.66%. Overall, the current technical stance is mildly bullish, supported by the monthly indicators and daily moving averages, despite some bearish signals in the weekly timeframe.